Until Labs

Until Labs is a well-funded, ambitious biotech startup tackling the profound challenge of reversible cryopreservation. Founded in 2020 and based in San Francisco, the company is initially focusing on creating a platform to preserve donor organs, which addresses a critical unmet need in transplantation while de-risking the science for more complex applications. With over $100 million in funding and a multidisciplinary team, Until is developing integrated workflows encompassing perfusion, cryoprotectants, and controlled cooling/rewarming to safely 'pause' and resume biological function.

Integrated reversible cryopreservation platform focusing on vitrification via five dimensions: perfusion & cryoprotectant loading, controlled cooling, uniform ultra-rapid rewarming (e.g., nanowarming), CPA removal/reperfusion, and AI/ML-enhanced organ assessment.

Until operates in a nascent field with few direct competitors. Traditional organ preservation relies on static cold storage or machine perfusion (e.g., TransMedics), which extend viability only to hours or a few days. Other groups are researching vitrification (e.g., academic labs, the Organ Preservation Alliance), but Until appears unique in its integrated engineering approach, substantial funding, and focus on developing a complete clinical system. Its main competition is the immense scientific difficulty of the problem itself.